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CCR5 Expression on Cells from
HLA-Matched Unrelated
Marrow Donors and
Graft-versus-Host DiseaseGraft-versus-host disease (GVHD) is a common
complication that is caused by donor T cells following
allogeneic hematopoietic cell transplant. Recently, the
functional state of T cells has been characterized by
their chemokine receptor expression pattern [1]. T
cells expressing chemokine receptor CCR5 contributeTable 1. Transplant outcomes of patients receiving unrelated marr
(+/2) or CCR5632 homozygous (2/2) donors.
+/+ (n 5 344) +/2 (n
Grades II-IV 309 (90%) OR 5 1 34 (87%) OR 5 0.77
Grades III-IV 124 (36%) OR 5 1 13 (33%) OR 5 0.89
Skin* 288 (84%) OR 5 1 18 (46%) OR 5 0.89
Liver* 159 (46%) OR 5 1 32 (82%) OR 5 0.65
Gut* 219 (64%) OR 5 1 14 (36%) OR 5 0.82
Chronic† 207 (60%) HR 5 1 19 (49%) HR 5 0.96
Relapse 66 (19%) HR 5 1 9 (23%) HR 5 1.71
Mortality 167 (49%) HR 5 1 24 (62%) HR 5 1.59
OR indicates odds ratio; HR, hazard ratio.
*Organ-specific graft-versus-host disease (GVHD) of any grade (1-IV).
†Clinical extensive chronic GVHD.to the rejection of solid organ allografts [2] and
development of murine GVHD [3-5]. A nonfunctional
mutant allele of CCR5, CCR5D32, is found with 10%
frequency in Caucasians [6,7]. In a study of renal-
transplant survival, patients homozygous for
CCR5D32 had significantly prolonged graft survival
compared to heterozygous or wild-type patients [8].
Here, we retrospectively compared outcomes among
patients receiving marrow grafts from unrelated do-
nors homozygous for CCR5D32 to those from donors
expressing CCR5.
We screened the donor DNA repository at Fred
HutchinsonCancerCenter for theCCR5D32mutation
by a PCR method [9]. Among 1273 donors, 9 were ho-
mozygous forCCR5D32.Recipients of those bonemar-
row (BM) grafts were predominantly cytomegalovirus
(CMV) patients (CMV 5 8; acute myelogenous leuke-
mia [AML] 5 1), and we therefore decided to confine
our study to the CMV patient group. Patients were 18
to 50 years old and transplanted between 1988 and
2000. They received cyclophosphamide (Cy) and frac-
tionated total body irradiation, unmanipulatedmarrow,
and GVHD prophylaxis with cyclosporine (CsA) and
methotrexate (MTX) [9]. A total of 344 CMV patients
had a CCR5 wild-type donor, 39 had a CCR5D32 het-
erozygous donor, and 8 had a CCR5D32 homozygous
donor. Logistic regression model was used to assess
the association between CCR5 genotype and acute
GVHD (aGVHD), and Cox regression was used for
chronicGVHD(cGVHD)and relapse.As shown inTa-
ble 1, there was less GVHD among patients whose do-
nor was CCR5D32 homozygous compared to patients
with a wild-type or heterozygous donor, although
most of the differences are not statistically significant.
The number of patients with a homozygous donor is
small, making it difficult to derive firm conclusions
even where results are suggestive of a true difference.
Moreover, there are several factors that have an impact
onGVHD, relapse, andmortality.With only 8 patients
with a homozygous donor, we made limited adjust-
ments. After controlling for severity of disease (catego-
rized as low [chronic phase] versus intermediate
[accelerated phase or blast crisis in remission] versusow grafts from CCR5 wild-type (+/+), CCR5632 heterozygous
5 39) 2/2 (n 5 8)
(0.28-2.10, P 5 .61) 6 (75%) OR 5 0.34 (0.07-1.75, P 5 .20)
(0.44-1.79, P 5 .74) 1 (13%) OR 5 0.25 (0.03-2.08, P 5 .20)
(0.37-2.11, P 5 .79) 4 (50%) OR 5 0.19 (0.05-0.80, P 5 .02)
(0.33-1.30, P 5 .22) 2 (25%) OR 5 0.39 (0.08-1.95, P 5 .25)
(0.42-1.61, P 5 .57) 5 (63%) OR 5 0.95 (0.22-4.05, P 5 .95)
(0.60-1.53, P 5 .85) 3 (38%) HR 5 0.45 (0.14-1.41, P 5 .17)
(0.85-3.43, P 5 .13) 3 (38%) HR 5 1.80 (0.57-5.71, P 5 .32)
(1.04-2.44, P 5 .03) 4 (50%) HR 5 1.01 (0.37-2.71, P 5 .99)
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homozygous group are similar to the unadjusted results
(data not shown). Similarly, after adjusting for number
of mismatched HLA alleles (considering HLA-A, -B,
-C, -DRB1, -DQB1, and -DPB1, with a range of 0 to
8 total mismatches in the 391 patients), the effects asso-
ciatedwith the homozygous group are similar to the un-
adjusted results (data not shown).
In summary, the absence of functional CCR5 in
marrow donors may be associated with less GVHD.
With only 8 patients having a homozygous donor,
these preliminary results are in need of larger numbers.
Therefore, we propose screening the sample reposi-
tory from the National Marrow Donor Program
Foundation to identify additional patients with
a CCR5D32 homozygous donor. Currently CCR5
antagonists are developed and approved for HIV
treatment [10]. Further studies may provide rationale
to develop novel treatments for GVHD.ACKNOWLEDGMENTS
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Institution Affects Association
between CMV Seronegative
Graft and Leukemic Relapse
after Pediatric HCT
Wereadwith interest the letter fromTravi and col-
leagues [1] reporting results from their own institution
that differed from those we recently published in the
Journal [2]. The letter inquired whether differing dis-
tributions of demographics or conditioning regimens
might explain why the similar, contemporary samples
yielded contrasting findings on whether donor/recipi-
ent cytomegalovirus (CMV) serostatus affects the inci-
dence of leukemic relapse after pediatric hematopoietic
cell transplantation (HCT). Here we reply to the ques-
tion, and offer a potential explanation of our own.
After stating the traditional view, establishedbefore
the current era ofCMVpreemptive therapy, that ‘‘sero-
negative recipients with a seronegative donor (D2/
R2) have shown an improved outcome’’ after HCT,
Travi et al. [1] reported that, amongpediatric recipients
at their institution, D2/R2 grafts were not associated
with improved outcome, either in relapse or nonrelapse
mortality (NRM). In contrast, our study of a similar pe-
diatric sample [2] yielded the novel finding that D2/
R2 grafts were significantly associated with poorer
outcome (higher incidence of relapse, inferior re-
lapse-free survival [RFS]) than other grafts. Because re-
lapse was rarely detected by Travi et al. [1] after 2 years
posttransplant, we compared 2-year incidence by insti-
tution and serostatus, using Figure 1B fromTravi et al.
[1] and Figure 2 from our article [2]. At 2 years post-
HCT, the 2 samples had similar cumulative incidences
